Joel Greenblatt Prothena Corp Public LTD CO Transaction History

Gotham Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$22.73 - $39.98 $586,070 - $1.03 Million	-25,784 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$30.27 - $49.22 $268,615 - $436,778	-8,874 Reduced 25.6%	25,784 $943,000
Q4 2021 Feb 14, 2022	BUY	$42.11 - $73.26 $694,183 - $1.21 Million	16,485 Added 90.71%	34,658 $1.71 Million
Q3 2021 Nov 15, 2021	BUY	$48.2 - $78.89 $618,695 - $1.01 Million	12,836 Added 240.51%	18,173 $1.29 Million
Q2 2021 Aug 16, 2021	BUY	$21.63 - $57.65 $115,439 - $307,678	5,337 New	5,337 $274,000

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $704M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.